Silence Therapeutics plc
SLN312
dyslipidemia
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for SLN312 in dyslipidemia are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Additional Ph1 presentations in 2026 Silencing diseases through precision engineered medicines created with proprietarysiRNA technology”